North Carolina-based Slate Medicines, Inc. will gain a Nasdaq listing through an all-stock reverse merger with Massachusetts-based Fulcrum Therapeutics, Inc. (Nasdaq: FULC), with the combined company adopting the Slate name and expected to trade under the ticker SLTE. The transaction is paired with an oversubscribed USD 245 million private placement led by Frazier Life Sciences, with participation from Forbion, RA Capital Management, Deep Track Capital, Foresite Capital, OrbiMed, RTW Investments, and Mingxin Capital.
The structure effectively gives privately held Slate control of Fulcrum's Nasdaq listing and residual cash. Pre-merger Fulcrum stockholders are expected to own 5% of the combined company, while Slate stockholders, including investors participating in the private placement, will own 95%. Fulcrum expects to contribute approximately USD 20.3 million in net cash and distribute an estimated USD 270 million cash dividend to its existing stockholders immediately before closing. The combined company's cash is expected to fund operations into 2029.
The transaction follows Fulcrum's June 2026 discontinuation of its pociredir sickle cell disease program after FDA feedback raised concerns over potential malignancy risks associated with inhibition of the PRC2 complex. Fulcrum subsequently initiated a strategic alternatives review, leaving the company without an active clinical development program of its own. The merger has received unanimous approval from both boards and is expected to close in Q4 2026, subject to stockholder approval and customary conditions including Hart-Scott-Rodino clearance.
The combined company's pipeline will be built around Slate's migraine programs. Lead asset SLTE-1009 is a monoclonal antibody designed to bind both pituitary adenylate cyclase-activating peptide (PACAP) and vasoactive intestinal peptide (VIP), with Slate proposing that broader neutralization of the PACAP/VIP pathway could improve on antibodies targeting PACAP alone. The antibody incorporates half-life extension to support subcutaneous dosing and potentially quarterly administration.
SLTE-1009 has received clearance to enter a Phase I study in Australia, with initial pharmacokinetic and safety data expected in mid-2027. The USD 245 million financing is expected to fund the program through a Phase II dose-ranging study in migraine patients. Slate is also developing SLTE-2100, a bispecific antibody combining PACAP/VIP and calcitonin gene-related peptide (CGRP) targeting, which is in lead optimization and expected to enter clinical trials in 2H 2027.
The financing gives Slate an unusually large capital base for a company whose lead program has yet to generate human data, reflecting growing investment around PACAP as a clinically validated alternative or complement to CGRP blockade in migraine prevention. Slate previously raised a USD 130 million Series A in February 2026, when SLTE-1009 was licensed from China's DartsBio Pharmaceuticals.